Wedelolactone, a naturally occurring coumestan, enhances interferon-γ signaling through inhibiting STAT1 protein dephosphorylation

Journal of Biological Chemistry

Volumn 288, Issue 20, 2013, Pages 14417-14427

  Chen, Zhimin ^a   Sun, Xiaoxiao ^a   Shen, Si ^a   Zhang, Haohao ^a   Ma, Xiuquan ^b   Liu, Jingli ^a   Kuang, Shan ^a   Yu, Qiang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROLIFERATION; DEPHOSPHORYLATIONS; DRUG CANDIDATES; NATURAL COMPOUNDS; NATURALLY OCCURRING; PROTEIN-TYROSINE PHOSPHATASE; SIGNAL TRANSDUCERS AND ACTIVATORS OF TRANSCRIPTIONS; TYROSINE PHOSPHATASE;

CELL DEATH; GENE EXPRESSION; PHOSPHATASES; PROTEINS; T-CELLS;

AMINO ACIDS;

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; MESSENGER RNA; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; SMALL INTERFERING RNA; SUPPRESSOR OF CYTOKINE SIGNALING 1; WEDELOLACTONE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE; GENE TARGETING; IL 8 GENE; INTRACELLULAR SIGNALING; IP 10 GENE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN DOMAIN; PROTEIN INDUCTION; SOCS1 GENE;

CYTOKINES/INTERFERON; PHOSPHATASE; STAT TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR GENE; TUMOR THERAPY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; COUMARINS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HEP G2 CELLS; HUMANS; INTERFERON-GAMMA; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PLANT EXTRACTS; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; STAT1 TRANSCRIPTION FACTOR;

EID: 84877909949     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.442970     Document Type: Article

References (57)

1. Horvath, C. M. (2000) STAT proteins and transcriptional responses to extracellular signals. Trends Biochem. Sci. 25, 496-502
2. Battle, T. E., and Frank, D. A. (2002) The role of STATs in apoptosis. Curr. Mol. Med. 2, 381-392 (Pubitemid 35452886)
3. Stephanou, A., and Latchman, D. S. (2003) STAT-1. A novel regulator of apoptosis. Int. J. Exp. Pathol. 84, 239-244
4. Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., and Schreiber, R. D. (1998) Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U.S.A. 95, 7556-7561 (Pubitemid 28293291)
5. Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D., and Darnell, J. E., Jr. (1996) Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon α and interferon γ. Proc. Natl. Acad. Sci. U.S.A. 93, 7673-7678 (Pubitemid 26277095)
6. Buard, A., Vivo, C., Monnet, I., Boutin, C., Pilatte, Y., and Jaurand, M. C. (1998) Human malignant mesothelioma cell growth. Activation of Janus kinase 2 and signal transducer and activator of transcription 1α for inhibition by interferon-γ. Cancer Res. 58, 840-847 (Pubitemid 28099501)
7. Chin, Y. E., Kitagawa, M., Su, W. C., You, Z. H., Iwamoto, Y., and Fu, X. Y. (1996) Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272, 719-722
8. Huang, Y. Q., Li, J. J., and Karpatkin, S. (2000) Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway. J. Biol. Chem. 275, 6462-6468
9. ten Hoeve, J., de Jesus Ibarra-Sanchez, M., Fu, Y., Zhu, W., Tremblay, M., David, M., and Shuai, K. (2002) Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol. Cell Biol. 22, 5662-5668 (Pubitemid 34815816)
10. Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678
11. Todd, J. A., Walker, N. M., Cooper, J. D., Smyth, D. J., Downes, K., Plagnol, V., Bailey, R., Nejentsev, S., Field, S. F., Payne, F., Lowe, C. E., Szeszko, J. S., Hafler, J. P., Zeitels, L., Yang, J. H., Vella, A., Nutland, S., Stevens, H. E., Schuilenburg, H., Coleman, G., Maisuria, M., Meadows, W., Smink, L. J., Healy, B., Burren, O. S., Lam, A. A., Ovington, N. R., Allen, J., Adlem, E., Leung, H. T., Wallace, C., Howson, J. M., Guja, C., Ionescu-Tîrgoviste, C., Simmonds, M. J., Heward, J. M., Gough, S. C., Wellcome Trust Case Control Consortium, Dunger, D. B., Wicker, L. S., and Clayton, D. G. (2007) Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet. 39, 857-864 (Pubitemid 47018195)
12. Zhang, S., Chen, L., Luo, Y., Gunawan, A., Lawrence, D. S., and Zhang, Z. Y. (2009) Acquisition of a potent and selective TC-PTP inhibitor via a stepwise fluorophore-tagged combinatorial synthesis and screening strategy. J. Am. Chem. Soc. 131, 13072-13079
13. Iversen, L. F., Moller, K. B., Pedersen, A. K., Peters, G. H., Petersen, A. S., Andersen, H. S., Branner, S., Mortensen, S. B., and Moller, N. P. (2002) Structure determination of T cell protein-tyrosine phosphatase. J. Biol. Chem. 277, 19982-19990 (Pubitemid 34967521)
14. Elchebly, M., Payette, P., Michaliszyn, E., Cromlish, W., Collins, S., Loy, A. L., Normandin, D., Cheng, A., Himms-Hagen, J., Chan, C. C., Ramachandran, C., Gresser, M. J., Tremblay, M. L., and Kennedy, B. P. (1999) Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283, 1544-1548
15. Klaman, L. D., Boss, O., Peroni, O. D., Kim, J. K., Martino, J. L., Zabolotny, J. M., Moghal, N., Lubkin, M., Kim, Y. B., Sharpe, A. H., Stricker-Krongrad, A., Shulman, G. I., Neel, B. G., and Kahn, B. B. (2000) Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell Biol. 20, 5479-5489 (Pubitemid 30482885)
16. You-Ten, K. E., Muise, E. S., Itié, A., Michaliszyn, E., Wagner, J., Jothy, S., Lapp, W. S., and Tremblay, M. L. (1997) Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatasedeficient mice. J. Exp. Med. 186, 683-693 (Pubitemid 27381533)
17. Hao, L., Tiganis, T., Tonks, N. K., and Charbonneau, H. (1997) The noncatalytic C-terminal segment of the T cell protein tyrosine phosphatase regulates activity via an intramolecular mechanism. J. Biol. Chem. 272, 29322-29329 (Pubitemid 27498226)
18. Kobori, M., Yang, Z., Gong, D., Heissmeyer, V., Zhu, H., Jung, Y. K., Gakidis, M. A., Rao, A., Sekine, T., Ikegami, F., Yuan, C., and Yuan, J. (2004) Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ. 11, 123-130 (Pubitemid 38111379)
19. Pôças, E. S., Lopes, D. V., da Silva, A. J., Pimenta, P. H., Leitão, F. B., Netto, C. D., Buarque, C. D., Brito, F. V., Costa, P. R., and Noël, F. (2006) Structure-activity relationship of wedelolactone analogues. Structural requirements for inhibition of Na+, K+-ATPase and binding to the central benzodiazepine receptor. Bioorg. Med. Chem. 14, 7962-7966
20. Diogo, L. C., Fernandes, R. S., Marcussi, S., Menaldo, D. L., Roberto, P. G., Matrangulo, P. V., Pereira, P. S., Franca, S. C., Giuliatti, S., Soares, A. M., and Lourenco, M. V. (2009) Inhibition of snake venoms and phospholipases A2 by extracts from native and genetically modified Eclipta alba: isolation of active coumestans. Basic Clin. Pharmacol. Toxicol. 104, 293-299
21. Kaushik-Basu, N., Bopda-Waffo, A., Talele, T. T., Basu, A., Costa, P. R., da Silva, A. J., Sarafianos, S. G., and Noël, F. (2008) Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. Nucleic Acids Res. 36, 1482-1496 (Pubitemid 351426102)
22. Upadhyay, K., Gupta, N. K., and Dixit, V. K. (2012) Development and characterization of phyto-vesicles of wedelolactone for hepatoprotective activity. Drug Dev. Ind. Pharm. 38, 1152-1158
23. Idris, A. I., Libouban, H., Nyangoga, H., Landao-Bassonga, E., Chappard, D., and Ralston, S. H. (2009) Pharmacologic inhibitors of IκB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol. Cancer Ther. 8, 2339-2347
24. Vender, J. R., Laird, M. D., and Dhandapani, K. M. (2008) Inhibition of NFκB reduces cellular viability in GH3 pituitary adenoma cells. Neurosurgery 62, 1122-1127; discussion 1027-1128
25. Tsai, C. H., Lin, F. M., Yang, Y. C., Lee, M. T., Cha, T. L., Wu, G. J., Hsieh, S. C., and Hsiao, P. W. (2009) Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin. Cancer Res. 15, 5435-5444
26. Lin, F. M., Chen, L. R., Lin, E. H., Ke, F. C., Chen, H. Y., Tsai, M. J., and Hsiao, P. W. (2007) Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells. Carcinogenesis 28, 2521-2529
27. Benes, P., Knopfova, L., Trcka, F., Nemajerova, A., Pinheiro, D., Soucek, K., Fojta, M., and Smarda, J. (2011) Inhibition of topoisomerase IIα: novel function of wedelolactone. Cancer Lett. 303, 29-38
28. Haspel, R. L., Salditt-Georgieff, M., and Darnell, J. E., Jr. (1996) The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EMBO J. 15, 6262-6268 (Pubitemid 26397899)
29. Chen, Z., Ma, X., Zhang, H., Sun, X., Shen, S., Li, Y., Gu, Y., Wang, Y., Yan, S., and Yu, Q. (2011) Negative regulation of interferon-γ/STAT1 signaling through cell adhesion and cell density-dependent STAT1 dephosphorylation. Cell. Signal. 23, 1404-1412
30. Ning, Y., Riggins, R. B., Mulla, J. E., Chung, H., Zwart, A., and Clarke, R. (2010) IFNγ restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-κB, BCL2 family members, and signaling to caspase-dependent apoptosis. Mol. Cancer Ther. 9, 1274-1285
31. Li, Y., Tang, Z. Y., Ye, S. L., Liu, Y. K., Chen, J., Xue, Q., Chen, J., Gao, D. M., and Bao, W. H. (2001) Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J. Gastroenterol. 7, 630-636 (Pubitemid 32994410)
32. Leonard, W. J. (2001) Role of Jak kinases and STATs in cytokine signal transduction. Int. J. Hematol. 73, 271-277
33. Wu, T. R., Hong, Y. K., Wang, X. D., Ling, M. Y., Dragoi, A. M., Chung, A. S., Campbell, A. G., Han, Z. Y., Feng, G. S., and Chin, Y. E. (2002) SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. J. Biol. Chem. 277, 47572-47580 (Pubitemid 36159277)
34. Liu, D., Scafidi, J., Prada, A. E., Zahedi, K., and Davis, A. E., 3rd. (2002) Nuclear phosphatases and the proteasome in suppression of STAT1 activity in hepatocytes. Biochem. Biophys. Res. Commun. 299, 574-580 (Pubitemid 36034584)
35. Mertens, C., Zhong, M., Krishnaraj, R., Zou, W., Chen, X., and Darnell, J. E., Jr. (2006) Dephosphorylation of phosphotyrosine on STAT1 dimers requires extensive spatial reorientation of the monomers facilitated by the N-terminal domain. Genes Dev. 20, 3372-3381 (Pubitemid 44969156)
36. Zhong, M., Henriksen, M. A., Takeuchi, K., Schaefer, O., Liu, B., ten Hoeve, J., Ren, Z., Mao, X., Chen, X., Shuai, K., and Darnell, J. E., Jr. (2005) Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle. Proc. Natl. Acad. Sci. U.S.A. 102, 3966-3971 (Pubitemid 40388539)
37. Mo, W., Zhang, L., Yang, G., Zhai, J., Hu, Z., Chen, Y., Chen, X., Hui, L., Huang, R., and Hu, G. (2008) Nuclear β-arrestin1 functions as a scaffold for the dephosphorylation of STAT1 and moderates the antiviral activity of IFN-γ. Mol. Cell 31, 695-707
38. Vijayakrishnan, L., Venkataramanan, R., and Gulati, P. (2011) Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol. Sci. 32, 25-34
39. Pardanani, A., Vannucchi, A. M., Passamonti, F., Cervantes, F., Barbui, T., and Tefferi, A. (2011) JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 25, 218-225
40. Wang, Y., Ma, X., Yan, S., Shen, S., Zhu, H., Gu, Y., Wang, H., Qin, G., and Yu, Q. (2009) 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells. Cancer Res. 69, 7302-7310
41. Detjen, K. M., Farwig, K., Welzel, M., Wiedenmann, B., and Rosewicz, S. (2001) Interferon γ inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut 49, 251-262 (Pubitemid 32675120)
42. Gooch, J. L., Herrera, R. E., and Yee, D. (2000) The role of p21 in interferon γ-mediated growth inhibition of human breast cancer cells. Cell Growth Differ. 11, 335-342 (Pubitemid 30457782)
43. Ruiz-Ruiz, C., Muñoz-Pinedo, C., and López-Rivas, A. (2000) Interferon-γ treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res. 60, 5673-5680
44. Condos, R., Raju, B., Canova, A., Zhao, B. Y., Weiden, M., Rom, W. N., and Pine, R. (2003) Recombinant γ interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients. Infect. Immun. 71, 2058-2064 (Pubitemid 36368740)
45. Horras, C. J., Lamb, C. L., and Mitchell, K. A. (2011) Regulation of hepatocyte fate by interferon-γ. Cytokine Growth Factor Rev. 22, 35-43
46. Cannon, G. W., Pincus, S. H., Emkey, R. D., Denes, A., Cohen, S. A., Wolfe, F., Saway, P. A., Jaffer, A. M., Weaver, A. L., and Cogen, L. (1989) Doubleblind trial of recombinant γ-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. 32, 964-973 (Pubitemid 19218375)
47. Miller, C. H., Maher, S. G., and Young, H. A. (2009) Clinical use of inter-feron- γ. Ann. N.Y. Acad. Sci. 1182, 69-79
48. Youlyouz-Marfak, I., Gachard, N., Le Clorennec, C., Najjar, I., Baran-Marszak, F., Reminieras, L., May, E., Bornkamm, G. W., Fagard, R., and Feuillard, J. (2008) Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Cell Death Differ. 15, 376-385
49. Scarzello, A. J., Romero-Weaver, A. L., Maher, S. G., Veenstra, T. D., Zhou, M., Qin, A., Donnelly, R. P., Sheikh, F., and Gamero, A. M. (2007) A mutation in the SH2 domain of STAT2 prolongs tyrosine phosphorylation of STAT1 and promotes type I IFN-induced apoptosis. Mol. Biol. Cell 18, 2455-2462 (Pubitemid 47025711)
50. Cool, D. E., Tonks, N. K., Charbonneau, H., Walsh, K. A., Fischer, E. H., and Krebs, E. G. (1989) cDNA isolated from a human T-cell library encodes a member of the protein-tyrosine-phosphatase family. Proc. Natl. Acad. Sci. U.S.A. 86, 5257-5261 (Pubitemid 19185534)
51. Sakaguchi, A. Y., Sylvia, V. L., Martinez, L., Smith, E. A., Han, E. S., Lalley, P. A., Shows, T. B., and Choudhury, G. G. (1992) Assignment of tyrosinespecific T-cell phosphatase to conserved syntenic groups on human chromosome 18 and mouse chromosome 18.Genomics 12, 151-154
52. Tiganis, T., Bennett, A. M., Ravichandran, K. S., and Tonks, N. K. (1998) Epidermal growth factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase. Mol. Cell Biol. 18, 1622-1634 (Pubitemid 28100928)
53. Ibarra-Sánchez, M. J., Wagner, J., Ong, M. T., Lampron, C., and Tremblay, M. L. (2001) Murine embryonic fibroblasts lacking TC-PTP display delayed G1 phase through defective NF-κB activation. Oncogene 20, 4728-4739 (Pubitemid 32762444)
54. Blaskovich, M. A. (2009) Drug discovery and protein tyrosine phosphatases. Curr. Med. Chem. 16, 2095-2176
55. Romsicki, Y., Kennedy, B. P., and Asante-Appiah, E. (2003) Purification and characterization of T cell protein tyrosine phosphatase reveals significant functional homology to protein tyrosine phosphatase-1B. Arch. Biochem. Biophys. 414, 40-50 (Pubitemid 36555443)
56. Mattila, E., Auvinen, K., Salmi, M., and Ivaska, J. (2008) The protein tyrosine phosphatase TCPTP controls VEGFR2 signalling. J. Cell Sci. 121, 3570-3580
57. Mattila, E., Pellinen, T., Nevo, J., Vuoriluoto, K., Arjonen, A., and Ivaska, J. (2005) Negative regulation of EGFR signalling through integrin-α1β1-mediated activation of protein tyrosine phosphatase TCPTP. Nat. Cell Biol. 7, 78-85 (Pubitemid 40123386)